1.69
-0.08 (-4.52%)
| Penutupan Terdahulu | 1.77 |
| Buka | 1.77 |
| Jumlah Dagangan | 20,928,311 |
| Purata Dagangan (3B) | 18,555,065 |
| Modal Pasaran | 1,083,121,664 |
| Harga / Jualan (P/S) | 6.04 |
| Harga / Buku (P/B) | 4.72 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 May 2026 |
| Margin Keuntungan | -119.54% |
| Margin Operasi (TTM) | -42.18% |
| EPS Cair (TTM) | -0.210 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 12,927.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 45.40% |
| Nisbah Semasa (MRQ) | 7.86 |
| Aliran Tunai Operasi (OCF TTM) | -204.34 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -142.38 M |
| Pulangan Atas Aset (ROA TTM) | -16.07% |
| Pulangan Atas Ekuiti (ROE TTM) | -45.35% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Geron Corporation | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.25 |
|
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.09% |
| % Dimiliki oleh Institusi | 81.26% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |